Why Do GLP-1s Cost Less in Other Countries?

The comparison that launched a thousand news segments: a month of Ozempic listed at $936 in the United States and $169 in Japan, about $103 in Germany and $93 in the United Kingdom [1] (figures verified 2026-09-14 against the Peterson-KFF brief, which published them on August 17, 2023 using June 30, 2023 exchange rates; they are 2023 list prices, not today’s consumer prices). Wegovy at its maintenance dose listed at $1,349 in the US against $328 in Germany and $296 in the Netherlands [1].

Those numbers come from a Peterson-KFF analysis published in August 2023 using June 2023 exchange rates, so treat them as an illustration of the gap rather than today’s price. The gap itself is real and has been documented repeatedly. The interesting question is why it exists, and whether it is closing.

This is a policy explainer, not medical advice. And to be direct about the practical upshot: the price gap is not a shopping opportunity for most Americans, for reasons covered below.

Reason one: other countries negotiate as a single buyer

In most wealthy countries, one national body decides whether a drug gets covered and at what price. England has NICE. Germany runs a price negotiation after a benefit assessment. Japan sets prices through a national fee schedule. These bodies can say no, and a manufacturer that wants access to the whole country has to accept the offered price.

The US has no equivalent for commercial insurance. Manufacturers set a list price, then negotiate confidential rebates with individual pharmacy benefit managers and insurers. Those rebates are substantial. Novo Nordisk has reported that rebates and other fees across all payers accounted for about 40% of the cost of Ozempic and Wegovy, and said it expected them to grow [2].

But rebates flow to payers, not necessarily to patients. Someone paying coinsurance on an unmet deductible is billed against the list price, not the rebated price. That is precisely the group Novo Nordisk named when it announced in February 2026 that it would cut the US list price for Wegovy, Ozempic and Rybelsus to $675 a month effective January 1, 2027, calling out people with high-deductible plans and coinsurance benefit designs [3].

Medicare got a negotiating tool in 2022 through the Inflation Reduction Act, and semaglutide was among the first 25 drugs negotiated. The resulting maximum fair price of $274 per 30-day supply takes effect January 1, 2027. But that applies only to Medicare.

Reason two: US patents last longer

This is the larger structural reason, and it explains why the gap is about to widen in a strange direction.

Novo Nordisk’s semaglutide patents expired in a cluster of major markets in 2026:

• Canada: data exclusivity expired January 4, 2026, and the core compound patent lapsed after missed maintenance fee payments [4]
• India: patent expired March 20, 2026
• China: compound patent expired March 20, 2026
• Brazil: patent expired March 2026

In the United States, Novo Nordisk stated in its 2025 Form 20-F that the compound patent expiry for Ozempic, Rybelsus and Wegovy is 2032. Reporting puts the core US patent expiration in December 2031, with formulation and device patents potentially pushing injectable generics toward 2033.

So for roughly six years, people in Canada, India, Brazil and China will have access to generic semaglutide that Americans will not.

What has actually happened in those countries?

Canada became the first G7 country to approve a generic semaglutide when Health Canada authorized Dr. Reddy’s injection on April 28, 2026 [5]. Apotex followed days later. Health Canada said it was reviewing eight more applications [6]. In Canada, generics are commonly 45% to 90% cheaper than brands once several are on the market, though the first generic is typically priced at 75% to 85% of the brand under provincial pricing rules. Ozempic itself lists at roughly CA$223 to CA$250 for four weeks in Canada, before pharmacy and wholesaler markups.

India saw the fastest and deepest price collapse. About ten manufacturers launched within days of the March 20, 2026 patent expiry, including Sun Pharma, Dr. Reddy’s, Zydus, Glenmark, Alkem, Natco, Eris and Torrent. Monthly prices ranged from roughly 1,290 to 8,000 rupees, against Novo Nordisk’s Indian retail range of 8,800 to 16,400 rupees, a discount of up to about 90% [7]. Sun Pharma’s diabetes brand started at about 750 rupees a week, roughly $8.

Brazil approved its first generic semaglutide pen, EMS’s Ozivy, on May 26, 2026, with production capacity for up to 40 million pens a year.

China was the exception. Its patent expired the same day as India’s, but more than a month later no Chinese generic had been approved, and Novo Nordisk still held the market while eleven applications sat in review.

Can Americans just buy it from Canada?

Almost certainly not, and this is where a lot of bad advice circulates.

FDA rules generally bar individuals from importing prescription drugs that are not FDA approved, and that includes foreign-labeled versions of drugs that are approved here. The agency describes narrow situations in which it may take a more permissive view of personal-use imports, but that is discretion, not a right [8].

There is a separate legal pathway, Section 804 of the Food, Drug, and Cosmetic Act, which allows states and tribes — not individuals — to import certain prescription drugs from Canada after developing a program and getting federal authorization [9]. Florida received authorization for such a program. It is a state procurement mechanism, not a consumer channel.

And the generics themselves are not available to you anyway. Dr. Reddy’s chief executive told the BBC the company has applied for approval in more than 80 countries and expects its generic GLP-1 in South America, Africa and most of Asia — but not in the US, UK or Europe, because of patent protection [10].

There are also safety arguments against the informal route. The AMA Journal of Ethics and US law enforcement have both raised concerns that importation weakens controls in a historically secure supply chain and opens a door to counterfeits [11]. Counterfeit semaglutide pens have been a documented problem globally. If you are considering any non-US source, talk to a healthcare provider and a pharmacist first.

What is most-favored-nation pricing and did it work?

Most-favored-nation pricing ties US prices to the lowest price paid by comparably developed countries. President Trump signed an executive order directing the approach on May 12, 2025, sent demand letters to manufacturers on July 31, 2025, and then announced a series of company-by-company agreements [12].

The GLP-1 agreement, announced November 6, 2025, was the largest. It set [12]:

• A $245 net price for Ozempic, Wegovy, Mounjaro and Zepbound in Medicare and Medicaid
• A $50 monthly Medicare copay
• TrumpRx cash prices near $350 for Ozempic and Wegovy and about $346 for Zepbound
• A $150 starting price for newly approved oral GLP-1s
• Guaranteed MFN prices on all new medicines from both companies
• Access to MFN prices for every state Medicaid program

By the time TrumpRx.gov launched on February 5, 2026, the advertised prices had gone lower than the November targets: Ozempic and the Wegovy pen from $199 a month, the Wegovy pill from $149, Zepbound from $299 [13].

The administration also worked the other side of the equation. On December 1, 2025, USTR, Commerce and HHS announced an agreement with the United Kingdom to raise the net price of new prescription drugs there by 25% [13].

So has the gap closed?

Partly, and unevenly.

On cash price, yes, dramatically. In early 2024 an uninsured American faced roughly $1,000 to $1,350 a month for branded semaglutide. By September 2026 the published cash prices are $149 to $499 depending on product and dose. That is within range of what several European countries pay at list.

On list price, not yet. Ozempic still lists at $1,027.51 and Wegovy at $1,349.02, which is what drives bills for people with coinsurance and unmet deductibles. The scheduled drop to $675 in January 2027 narrows that considerably [3].

On generics, the gap is about to get wider before it gets narrower. Canada, India, Brazil and China have generic or near-generic semaglutide markets now. The US does not expect one until the early 2030s.

The honest takeaway

The US pays more for semaglutide than peer countries for two reasons that are both policy choices: a fragmented purchasing system with no national negotiator for most Americans, and patent terms that run several years longer than in many other markets.

For an individual trying to afford the drug today, the useful conclusion is not “buy it abroad.” It is that the domestic cash market has moved a long way in two years, and the branded self-pay prices now available in the US are a fraction of what they were, without any of the legal or safety uncertainty attached to foreign sourcing.

Sources

1. How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? — Peterson-KFF Health System Tracker, 2023-08-17
2. Medicaid Coverage of and Spending on GLP-1s — KFF, 2026-01-16
3. Novo Nordisk announces significant reduction in US list price — Novo Nordisk, 2026-02-24
4. Ozempic generics set to test Canada’s drug budgets — Benefits and Pensions Monitor, 2026
5. Canada becomes the first G7 country to approve a generic version of semaglutide — Health Canada, 2026-04-28
6. Canada approves first generic version of Ozempic — Reuters, 2026-04-28
7. India is launching cheap weight-loss drugs — CNBC, 2026-03-23
8. Personal Importation — FDA, 2025-08-18
9. Importing Prescription Medications From Canada — GoodRx, retrieved 2026-09-14
10. Why Canadians can now get cheaper generic Ozempic and Americans can’t — BBC News, 2026
11. What Should Prescribers and Policy Makers Know About US Drug Importation? — AMA Journal of Ethics, 2024-04
12. Fact Sheet: Most-Favored-Nation Pricing — The White House, 2025-11-06
13. Fact Sheet: TrumpRx.gov Launch — The White House, 2026-02-05
14. International Prescription Drug Price Comparisons — RAND Corporation